Logo

EDAP

Edap Tms S.a.

EDAP

Edap Tms S.a. • NASDAQ
$2.38 ▼ -1.65% (-0.04)
Market Cap $88.99 M
52w High $3.05
52w Low $1.21
Dividend Yield 0%
P/E -4.33
Volume 19.44K
Outstanding Shares 37.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.879M ▼ $10.897M ▼ $-5.014M ▲ -36.127% ▼ $-0.13 ▲ $-4.221M ▲
Q2-2025 $16.043M ▲ $12.591M ▲ $-5.6M ▲ -34.906% ▲ $-0.15 ▲ $-5.127M ▲
Q1-2025 $13.558M ▼ $11.691M ▼ $-7.074M ▼ -52.176% ▼ $-0.19 ▼ $-5.355M ▼
Q4-2024 $20.318M ▲ $12.835M ▲ $-1.941M ▲ -9.553% ▲ $-0.052 ▲ $-3.097M ▲
Q3-2024 $13.099M $10.988M $-6.399M -48.851% $-0.17 $-5.354M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.567M ▼ $61.464M ▼ $38.143M ▼ $23.321M ▼
Q2-2025 $16.265M ▼ $68.343M ▼ $40.521M ▲ $27.822M ▼
Q1-2025 $22.825M ▼ $74.976M ▼ $40.518M ▼ $34.458M ▼
Q4-2024 $29.836M ▲ $86.063M ▲ $45.167M ▲ $40.896M ▼
Q3-2024 $25.482M $79.043M $36.401M $42.642M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $0 ▲ $0 ▲ $0 ▲ $0 ▼ $0 $0 ▲
Q2-2025 $-6.352M ▲ $-4.657M ▲ $-1.599M ▼ $60.943K ▲ $0 ▲ $-6.255M ▲
Q1-2025 $-7.445M ▼ $-5.339M ▼ $-1.303M ▼ $-1.253M ▼ $-30.895M ▼ $-6.642M ▼
Q4-2024 $-2.069M ▲ $0 ▲ $0 ▲ $0 ▼ $30.895M ▲ $0 ▲
Q3-2024 $-6.399M $-4.859M $-979K $614K $-30.212M $-5.838M

Revenue by Products

Product Q4-2016Q2-2018Q4-2018Q1-2020
Licenses and Others
Licenses and Others
 $0 ▲$0 ▲$0 ▲$0 ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲
HIFU Treatments and Devices Leased
HIFU Treatments and Devices Leased
 $0 ▲$0 ▲$0 ▲$0 ▲
Parts and Services
Parts and Services
 $0 ▲$0 ▲$10.00M ▲$0 ▼
Product
Product
 $0 ▲$10.00M ▲$30.00M ▲$0 ▼
High Intensity Focused Ultrasound HIFU
High Intensity Focused Ultrasound HIFU
 $0 ▲$0 ▲$0 ▲$0 ▲
Urology Devices and Services UDS
Urology Devices and Services UDS
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement EDAP’s revenue has grown compared with several years ago but has been relatively flat more recently, suggesting the core business is established but not yet scaling rapidly. Gross profit has remained positive, which means the products themselves create value above their direct costs. However, operating income and net income have moved into loss territory in the last couple of years, likely reflecting higher spending on sales, marketing, and R&D to drive future growth. Overall, the company is still in an investment phase, trading current profitability for expansion and innovation.

Balance Sheet

Balance Sheet The balance sheet shows a business with modest size, limited debt, and a still-meaningful cash cushion, although that cash has been trending down. Equity has also declined in recent years, reflecting cumulative losses as the company invests ahead of revenue. Debt levels appear manageable relative to assets and cash, which reduces financial strain but still requires close monitoring if losses persist. In short, EDAP does not look overleveraged, but its financial flexibility depends on stabilizing or improving performance over time.

Cash Flow

Cash Flow EDAP has been using cash rather than generating it, with operating cash flow modestly negative in recent years. Free cash flow has also been negative, indicating that the business is not yet self-funding and still relies on its cash reserves and external financing to support operations and growth. Capital spending appears relatively light, so the main cash drain is likely operating expenses, including R&D and commercial expansion. This pattern is typical for a medtech company pushing innovation but adds pressure to eventually convert clinical and commercial progress into stronger cash generation.

Competitive Edge

Competitive Edge EDAP occupies a specialized niche in therapeutic ultrasound, particularly in focused ultrasound for prostate and other conditions, which gives it a differentiated position within medical devices. Its main strengths are proprietary HIFU technology, a long history in ultrasound, growing clinical evidence, and regulatory clearances that are not easy for new competitors to replicate. The decision to concentrate on the HIFU segment strengthens its strategic focus and aligns resources with its highest-growth area. At the same time, the company competes against larger device manufacturers with deeper pockets, and success depends on continued physician adoption, favorable reimbursement, and strong real‑world clinical outcomes.

Innovation and R&D

Innovation and R&D Innovation is clearly at the center of EDAP’s strategy. The company is extending its HIFU platform beyond prostate cancer into areas like endometriosis and benign prostatic hyperplasia, while also exploring next‑generation approaches such as histotripsy and AI‑enhanced imaging. This creates meaningful long‑term opportunity if clinical trials and regulatory processes go well, as it would broaden the addressable market and deepen the technology moat. However, this innovation push is expensive, contributes to current losses, and carries uncertainty around trial results, approvals, and actual market uptake once products are launched.

Summary

EDAP is a small but technologically advanced medtech company trading near-term profitability for long-term growth in focused ultrasound treatments. Financially, it shows steady but not explosive top‑line progress, ongoing losses, and negative cash flow, all cushioned by modest leverage and remaining cash resources. Strategically, its strength lies in differentiated HIFU technology, clinical validation, and a growing pipeline of new indications, which together support a meaningful competitive moat. The core tension for observers is whether and how quickly this innovation and clinical progress will translate into stronger, more sustainable revenue and cash flow before financial flexibility tightens; outcomes here will likely drive the company’s longer‑term trajectory.

NEWS

November 20, 2025 · 7:30 AM UTC

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU

Read more

November 18, 2025 · 7:00 AM UTC

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

Read more

November 6, 2025 · 7:30 AM UTC

EDAP Reports Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 7:00 AM UTC

EDAP to Present at Jefferies Global Healthcare Conference in London

Read more

October 27, 2025 · 7:00 AM UTC

EDAP to Participate in the UBS Global Healthcare Conference

Read more